









Markets
/
Stocks
/
nasdaq-roiv
/

Roivant Sciences Ltd

ROIV



View Detailed Chart

22.410USD

+0.620+2.85%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

15.46BMarket Cap

LossP/E TTM



Roivant Sciences Ltd

22.410

+0.620+2.85%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+2.85%

5 Days

+1.40%

1 Month

+10.56%

6 Months

+95.72%

Year to Date

+89.43%

1 Year

+93.69%

View Detailed Chart

TradingKey Stock Score of Roivant Sciences Ltd

Currency: USD Updated: 2025-12-19

Key Insights

Roivant Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 42/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.27.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Roivant Sciences Ltd's Score

Industry at a Glance

Industry Ranking

42 / 158

Overall Ranking

110 / 4582

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.273

Target Price

+15.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Roivant Sciences Ltd Highlights

StrengthsRisks

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.05M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -40.84, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 526.70M shares, decreasing 17.17% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.07K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.15.